Headache News and Research

Latest Headache News and Research

New web tool offers many capabilities vital to bacteria mutation research

In 1943, two scientists named Max Delbrück and Salvador Luria conducted an experiment to show that bacteria can mutate randomly, independent of external stimulus, such as an antibiotic that threatens a bacterial cells' survival.

15 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Study: COVID-19 vaccines safe for IBD patients

Patients with inflammatory bowel diseases (IBD) do not appear to have increased risk of side effects from the Pfizer or Moderna COVID-19 vaccines, according to a recent Cedars-Sinai study published online and upcoming in print in the American Journal of Gastroenterology.

9 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

7 Jun 2021

Around 5% of children develop long COVID-19 symptoms, suggests new study

A new study, by researchers at University College London (UCL) in the UK, shows that even though children rarely develop symptomatically severe COVID-19, the prevalence of long COVID in children with a history of infection is over 4.5%.

7 Jun 2021

Could sustained inflammation following mild to moderate COVID-19 be a driver of long COVID?

A new study describes the discovery of sustained though low-level rises in inflammatory mediators and immune cells, as well as the loss of some subsets of naïve un-activated cells. This may indicate a widespread though muted immune-mediated inflammatory response in these patients.

7 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Mental health effects common among mild and severe cases of COVID-19

Findings on mental health outcomes of COVID-19 infection show frequent symptoms associated with lasting neurological symptoms.

4 Jun 2021

Three cases of stroke reported in young adults following covid-19 vaccination

Clots in the arteries (arterial thrombosis) are the most common cause of stroke (ischemic stroke) and have been reported in detail for the first time in young adults who received the Oxford–AstraZeneca covid-19 vaccine in a letter from UK stroke specialists published online in Journal of Neurology Neurosurgery & Psychiatry.

4 Jun 2021

Could certain genes be associated with a loss of smell in some COVID-19 patients?

Researchers at the 23andMe COVID-19 Team, who help search for genetic links associated with the severity of COVID-19, found that the genes UGT2A1 and UGT2A2 may be associated with the loss of smell in those infected with SARS-CoV-2.

2 Jun 2021

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

1 Jun 2021

Unique observational tool developed for assessing children with concussion

A research team led by scientists at Université de Montréal has developed a unique observational tool for assessing children up to 5 years of age who have had a concussion.

1 Jun 2021

Neuropathology of COVID-19 patients caused by infection of brain pericytes

Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.

31 May 2021

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

In the Philippines, in the early months of the COVID-19 pandemic, there occurred a supply shortage of hydroxychloroquine and methotrexate. Limited access to medication and the life changes caused from the COVID-19 pandemic may prompt patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) to experience disease flares.

29 May 2021

New tool will help identify the most promising protein molecules for drug development

A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.

28 May 2021

Enough to wreck their rest: $10,322 for a sleep study

José Mendoza's snoring was bad — but the silence when he stopped breathing was even worse for his wife, Nancy.

27 May 2021

Neurocognitive symptoms persist 6 months post-infection with long COVID

According to the World Health Organization (WHO), COVID-19 long-haulers are people who experience symptoms such as body ache, fatigue, shortness of breath, headache, difficulty concentrating, loss of taste or smell, or other health issues long after they test negative for the virus. It can be defined as having serious and prolonged symptoms three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

26 May 2021